Pulmonary fibrosis is called fibrosing alveolitis or interstitial fibrosis, among other things. It is a non-specific condition in which the lungs respond to damage by the production of scar tissue (fibrosis). This leads to stiffness of the lungs and difficulties clearing secretions. It also interferes with gas exchange. Its causes include numerous bacterial, viral or fungal infections and inhaled toxins, dusts (organic and inorganic) and chemicals.
Occasionally stomach contents can be inhaled to the detriment of the lungs. Other diseases are involved less often, such as certain autoimmune disorders (mistaken immune response to healthy processes), arcoidosis (a multi-system inflammatory disorder), or collagenvascular diseases (rheumatoid arthritis, lupus, polyarteritis nodosa, scleroderma and dermatomytosis). This disease is often an unwanted result of radiation therapy or chemotherapy. The standard treatments have limited success.
Oxidative stress plays an important role in the causes and conditions of many types of pulmonary fibrosis. J. Behr and his group of pulmonologists from the University of Munich studied this phenomenon both in laboratory cultures and in pulmonary fibrosis patients. Because pulmonary fibrosis is an inflammatory disorder, their treatment includes therapy to suppress the immune inflammatory response. With the help of N AC, patients' pulmonary function tests improved and the number of oxidative breakdown products fell. By using aerosolized N AC, Z. Borok from the NIH (National Institute of Health) reversed the oxidant-antioxidant imbalance in pulmonary fibrosis patients. Both NAC and aerosol glutathione have shown success in this situation. Clearly, both oral and inhaled NAC can successfully raise pulmonary glutathione levels.
In pulmonary fibrosis, fibroblasts-cells in part responsible for the fibrous scar tissue-grow excessively in both number and activity. Tissue cultures made of these cells revealed that the presence of glutathione down-regulated their growth, implying that glutathione may slow the progress of pulmonary fibrosis.
Case study
With a background in law from her native France, Nona became actively involved with business and philanthropic pursuits in Canada. She was a 41 year-old mother of three sufferingfrom Hodgkin's disease and requiring both chemotherapy and radiotherapy.
Although these treatments cured her of Hodgkin's disease, the treatments left her lungs scarred - the condition of pulmonary fibrosis. Her interests had to be dropped as her breathing deteriorated. She ended up staying at home, using home oxygen and many medications.
Despite all interventions, her pulmonary function tests (PFT's) continued to fall. After six weeks of Immunocal 20 grams/day she went back to her pulmonary doctor, claiming she could breath again. Thinking there might be a placebo effect; the physician repeated her pulmonary function tests, which showed her back at about 90% of nor7'al values.
To eliminate other possibilities, the Immunocal was withdrawn. She subsequently deteriorated
again. Three weeks after reinstating the lmmunocal, her PFT's went back up to 95% of normal values. She promised herself never to stop again.
CONCLUSION
An impressive amount of research has clarified the critical importance of antioxidants and glutathione in all these pulmonary diseases. Unlike most other tissues, the lungs can use glutathione as-is - through direct contact - rather than having to first absorb its precursors and then manufacture it. There are many ways to elevate pulmonary glutathione , including oral, intravenous and inhaled therapies. In the next few years we will see increased use of these products to raise glutathione levels in acute, chronic and critical care patients.
See the article "LUNG DISEASE in Orlando" for the REFERENCES
Immunocal and Immunocal Platinum are the ONLY Dietary supplements, patented and scientifically PROVEN to consistently raise glutathione levels and enhance the human immune system!
www.video-wellness.com
www.jrobwellness.com
No comments:
Post a Comment